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It is a  common observation that  many tumors of unquestionable  imnmnogenicity 
grow  progressively and  eventually  kill  their  syngeneic  host.  This  is  observed,  for 
instance,  with  many  methylcholanthrene-induced  tumors  that  are  able  to  elicit 
concomitant immunity (1-3) as well as a  measurable cytolytic T  lymphocyte (CTL) ~ 
response during the onset of tumor  growth.  It is possible that  some tumors outpace 
the  immune  defenses  of the  host  by  their  ability to  multiply and  metastasize  very 
rapidly. However, this is certainly not  a  general explanation, since for some tumors 
an initial period of growth is followed by a  period of stagnation or partial regression 
followed in turn by a resumption of tumor growth and death of the host. Mastocytoma 
P815 belongs to this category (4-6), where a partial immune rejection of the tumor by 
the syngeneic host is often observed but very rarely results in the complete elimination 
of the tumor cells. 
Evidence suggesting that suppressor cells may be the cause of this phenomenon has 
been  presented  by Takei  et  al.  (4,  7),  who  reported that  suppressor T  lymphocytes 
capable of inhibiting specifically the development of a  CTL response against masto- 
cytoma subline P815-12 appeared in the spleen after a period of partial rejection. On 
the other hand,  Biddison and Palmer (5)  showed that  tumor cells of subline P815-Y 
that  were collected from  the peritoneal cavity a  few days after the partial rejection 
phase  were  much  less sensitive than  the  original tumor  cells to  CTL  found  among 
peritoneal exudate cells of tumor-bearing animals. They suggested that this could be 
due  either  to  the  emergence  of  stable  antigen-loss  variants  or  to  a  modulation 
phenomenon. 
We report here the results of experiments aimed at evaluating the contribution of 
immunosuppression and tumor cell modification in the escape of P815-X2 tumor cells 
after a  nearly complete elimination by the immune defenses of the syngeneic host. 
Materials  and  Methods 
Animals.  DBA/2  mice were  derived from  breeders obtained  from J.  L.  Gunner  (Institut 
Pasteur, Paris). The mice used in the experiments, indifferently males or females, were between 
10 and  14 wk old. 
* Supported by Fonds National de la Recherche Scientifique, Brussels, Belgium. 
i Abbreviations used in  this paper: CTL,  cytolytic T  lymphocytes;  DME,  Dulbecco's  modified  Eagle's 
medium;  FCS,  fetal  calf serum;  i.p.,  intraperitoneally;  tlAT,  10  4 M  hypoxanthine,  3.8  X  10-'  M 
aminopterin,  1.6 x  10  5 M 2-deoxythymidine; MI,TC. mixed lymphocyte  tumor cell culture. 
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Culture and Cloning Conditions of Tumor Cells.  Our P815 subline was P815-X2.  The P815 cells 
were cultured in Petri dishes (Falcon  1001;  Falcon Labware, Div. of Becton, Dickinson & Co., 
Oxnard, CA) in Dulbecco's modified Eagle's medium  (DME)  (1600;  Grand  Island Biological 
Co., Grand  Island,  NY)  supplemented  with  5-10%  fetal calf serum  (FCS)  in an  atmosphere 
containing 8% CO2. 
P815  clones were isolated by a  limiting dilution procedure:  diluted  P815 cells resuspended 
in medium containing 10-20% FCS were distributed into microplates (96 round-bottom wells; 
Linbro Chemical Co., Hamden, CT). Plating efficiency was ~0.7-0.9. 
Azaguanine-resistant Mutants.  Azaguanine-resistant  (aza  r)  mutants  were selected in limiting 
dilution conditions in culture medium supplemented  with  10% FCS that  contained  10 #g/ml 
of azaguanine (ICN Nutritional Biochemicals, Cleveland, OH). We used mutants  that died in 
a  culture medium supplemented  with  10 .4 M  hypoxanthine  (Merck AG, Darmstadt,  Federal 
Republic of Germany),  3.8  X  10 .7 M  aminopterine  (ICN Nutritional  Biochemicals), and  1.6 
×  10 .5 M  2-deoxythymidine (Merck Ag) (HAT). 
Injection ofP815 Cells.  P815  cells were injected  intraperitoneally  (i.p.)  in  DBA/2  mice in 
DME that  contained no FCS. For the production of ascites cells, DBA/2 mice, given 700-750 
rad of gamma radiation from a cesium source, were injected i.p. with 2 X  l0  s P815 cells. Ascites 
cells were collected 3-6 d  later. 
Quantitation of Intraperitoneal P815 Cells by Colony Assay.  Mice were injected i.p. with 3 ml of 
DME. A  0.3-ml sample of intraperitoneal  fluid was immediately collected with a  syringe and 
transferred to a  tube that contained 6/~1 of heparin  (H-3125; Sigma Chemical Co., Sigma, St. 
Louis, MO). The cells were diluted in DME that  contained  1% FCS. Aliquots of 0.2 ml were 
mixed  in  a  petri  dish  (Falcon  1007)  with  2  ml  DME  that  contained  10%  FCS  and  0.4% 
Bactoagar (Difco Laboratories, Detroit, MI). After a  3- to 4-d incubation at 37°C, the colonies 
that  contained  more than  six cells were counted.  The number of living intraperitoneal  P815 
cells was estimated taking into account  the cloning efficiency of in vitro growing P815, which 
was ~0.3.  We verified with control animals that  peritoneal exudate cells do not form colonies 
under those conditions. 
To distinguish normal and azaguanine-resistant  tumor cells growing in the same peritoneal 
cavity, the cells were plated in agar containing either 10/~g/ml of azaguanine or HAT medium. 
Normal  P815  cell  populations  contained  <10 .5  cells  capable  of  growing  in  azaguanine 
containing  medium,  while azaguanine  resistant  populations  contained  10  .6  cells capable  of 
multiplying in HAT medium. 
CTL  Clones.  The  derivation  of a  CTL  clone  specific  for  P815  (CTL-P35:10)  has  been 
described (8).  Other CTL clones were obtained by a  similar procedure as follows. Spleen cells 
(3 ×  l0  T) from mice immunized 4-15 wk previously with either irradiated  (10,000 tad) P1 cells 
or living cells from P815 turn- variant P89 were cultured in mixed leukocyte-tumor cell culture 
(MLTC)  with 3  ×  105 stimulator cells. The origin of the stimulator cells is given below. The 
MLTC were established  in  15 ml of DME supplemented with L-arginine HCI (116 mg/liter), 
L-asparagine (36 rag/liter), x.-glutamine (216 mg/liter), glucose (4.5 g/liter final concentration), 
10  mM  Hepes,  5  X  10 -5  M  2-mercaptoethanol,  and  10%  FCS  (vol/vol).  Cultures  were 
maintained  in  tissue  culture  flasks  (3013  Falcon)  kept  in  an  upright  position  at  37°C  in  an 
atmosphere of air with 8% CO2. After 7 d  of incubation,  MLTC cells were cloned by limiting 
dilution.  Limiting numbers  of MLTC  cells were plated  with  7  ×  l0  b irradiated  (2,000  rad) 
DBA/2  spleen  cells and  irradiated  (5,000  rad)  stimulator  cells  (3  X  103) that  were used  for 
MLTC.  Microcultures were prepared  in round-bottomed  microtiter plates  (Titertek, cat.  no. 
76-213-05;  Flow Laboratories, Rockville, MD) and contained  150 #1 of DME supplemented as 
for  MLTC,  except  that  supernatant  (25-50%)  from  secondary  mixed leukocyte culture  was 
added  as a  source of T  cell growth factors  (9).  The plates were maintained  for 6-8 d  at  37°C 
in an atmosphere of air with 8% CO~. After 7 d, aliquots from each microculture were tested for 
cytolytic activity against the appropriate  target cells, as described (10). 
CTL from selected microcultures were transferred  to cultures containing 5 ×  106 irradiated 
(2,000  rad)  DBA/2  spleen  cells,  105  irradiated  (5,000  rad)  P815  stimulator  cells in  1 ml  of 
supernatant-supplemented  medium  as  described  above.  For subsequent  cells transfers  (every 
3-5 d), 5 ×  104 cells were transferred to new, identical  1-ml cultures. 
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of the mice taken as a source of immune spleen cells, and Y is the serial number of the clone. 
The stimulator cells used to isolate the new CTL clones described herein were as follows: for 
CTL-PI:3, P1; for CTL-P89:15, P89;  for CTL-P89:20, cells of immunoselected clone P1-20-4 
described in Results. 
Measurement of the Lysis of P815 Cells" by  CTL  Clones with  a  Colony Assay.  P815  cells  were 
collected from the peritoneal cavity, counted, resuspended in DME containing 10% FCS and 
directly mixed with CTL clones at various effector-to-target ratios in a volume of 200/~l in 96- 
well round-bottomed microplates. After an incubation of 3 h at 37°C, 150/~1 of each well was 
mixed with 1 ml DME containing 10% FCS and 0.4% Bactoagar in a 9.6-cm 2 plate (Linbro 76- 
04%05; Flow Laboratories). After a 3-to-4-d incubation  at 37°C the P815 colonies were counted. 
Chromium Release Assays.  Cytolytic assays were performed as described previously (10) with 
SICr-labeled  target  cells. All assays  were  performed  in DME containing 5%  FCS  in conical 
microplates (Titertek, cat. no. 76-223-05; Flow Laboratories) with 2,000 targets per well. 
Selection with  CTL  Clones.  The  selection  of antigen-loss variants with  CTL  clones  was 
described elsewhere  (11). Briefly,  106 P815 cells were  mixed with the appropriate CTL clone 
(2-4 ×  106 cells) in 2-5 ml of medium and incubated for 4 h. A portion of the selected  cell 
suspension was put in culture to serve as a source  of cells for a second selection. The selected 
P815 cells were also cloned in limiting dilution. Selected P815 clones were transferred to petri 
dishes for continuous culture. 
Detection of Antigen Expression on P815 Clones by a Growth Inhibition Assay.  The cells to be tested 
were  cultured under limiting dilution conditions, and 7-10 d  later, aliquots (20-50 #l)  from 
positive wells  were  transferred to  round-bottomed microplates. A  10-fold  dilution was  also 
prepared in DME containing 5% FCS. The cells were incubated alone or together with 104 cells 
from the appropriate CTL clone. Controls were prepared with cells from the original P1 clone. 
After 2-3 d, the wells were examined microscopically for the presence of a  large number of 
growing tumor cells. Subsequent chromium release  tests indicated that the growing cells were 
always resistant to the CTL clone used in the assay. 
Results 
Partial Rejection  and Subsequent  Escape of P815.  To follow the fate of P815-X2 cells 
injected intraperitoneally in syngeneic DBA/2 mice, we repeatedly collected samples 
from the peritoneal cavity and estimated the number of viable tumor cells with an 
agar colony assay.  Representative results obtained after the  injection of 600  tumor 
cells are shown in Fig. i. P815 cells multiplied exponentially to reach a number higher 
than  10  a  around  day  10  after  injection. In  some  mice,  the  number of P815  cells 
continued to increase and the animals died around day 20. In others, a  sudden drop 
in  the  number of tumor  cells  was  observed  between  10  and  17  d  after  injection 
together with a large increase in the number of lymphocytes and macrophages present 
in the peritoneal cavity. The decrease in the number of tumor cells was very variable 
flora one mouse to another. For some mice, the number of P815 cells dropped from 
> 108 to < 104. This low level of intraperitoneal P815 cells was observed during periods 
varying from a few days to 3 wk. Eventually however, the P815 cells multiplied again 
and all the mice died. 
The  partial  rejection  phase  was  never observed  for  mice  that  had  received  an 
immunosuppressive dose  of  600  rad  of  gamma  radiation  a  few  hours  before  the 
injection of tumor cells.  Thus,  it  appears  that,  when  P815  cells  undergo a  potent 
immune rejection by  the  host,  a  few  surviving cells  always escape  and  eventually 
multiply and kill the mice. 
Rejection  of Newly  Injected  P815  Cells  at  the  Time  of P815  Escape.  To  determine 
whether P815 tumor escape could be due to a  suppression of the anti-P815 immune 
response,  we  tested  whether,  at  the  time of tumor cell  escape,  the  mice were  still UYTTENHOVE,  MARYANSKI,  AND  BOON  1043 
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Fla.  l.  Four DBA/2 mice were injected i.p. with 600 living cells of P1, a  P815 clone. At various 
times thereafter, samples of the intraperitoneal fluid were collected and the number of living P815 
cells was estimated in an agar colony test. Each curve represents an individual mouse and ends on 
the last sampling before the death of the animal. 
capable of rejecting control P815 cells. For this experiment we used a P815 clone (P 1) 
and  an  azaguanine-resistant  mutant  derived  from it  (Pl.azar).  P1  and  Pl.aza  r are 
equally tumorigenic. The number of each cell  type present  in  the peritoneal cavity 
was estimated by plating the peritoneal content in agar with HAT medium, where 
only P1 formed colonies, or with azaguanine, where only Pl.aza  r formed colonies. 
A  representative  experiment  is  shown in  Fig.  2A.  A  DBA/2 mouse was injected 
with 600 P1  cells.  These cells  were largely rejected around day 20.  By day 31,  they 
were again multiplying rapidly. Pl.aza  ~ cells  maintained in vitro were then injected 
in the same peritoneal cavity. While the P1 cells continued to grow rapidly and killed 
the host a  few days later, the Pl.aza  ~ cells  were completely eliminated in a  few days. 
This showed that the animal where tumor escape was occurring was still  capable of 
rejecting P815 cells  and the the escaping tumor cells  were resistant to this anti-P815 
response. 
Three independent experiments of the kind described in Fig. 2 A were performed. 
The  Pl.aza  ~ cells  injected  at  the  time  of tumor  escape  were  invariably  rejected. 
Concordant results were obtained when mice were first injected with Pl.aza  ~  cells and 
injected with P1 cells at the time of tumor escape. To exclude the possibility that our 
results  might be due to problems of adaptation of in  vitro growing cells  to in  vivo 
conditions,  we  injected  mice  in  which  P1  cells  were  escaping  with  Pl.aza  r  cells 
collected  from  ascites  of irradiated  animals.  Similar  results  were  obtained  in  five 
independent experiments (Fig.  2 B). We also verified that P I.aza  ~  cells obtained either 109 
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Ftc.  2.  Two DBA/2 mice were injected i.p. with 600 P I cells (--0--).  At various times thereafter, 
samples of the peritoneal fluid weie collected and the number of P1  cells was estimated in an agar 
colony  assay.  On  the  day  indicated on  the  graph,  3  X  l0  b  Pl.aza  r  cells obtained  from  in  vitro 
culture  (A) or collected from  the ascites of an  irradiated DBA/2  mouse  (B)  were injected i.p.  into 
the test animal (IO--)  or into control DBA/2 mice (- -Q)- -). The number of viable Pl and Pl.aza  r 
cells  in  the  peritoneal  cavity  was  estimated  by  plating  samples  in  agar  containing  HAT  or 
azaguanine, respectively. 
from  ascites or from  long-term culture multiplied exponentially without  significant 
latency in control  mice and  in  mice  that  had been  injected  i.p. with  600  cells  10  d 
before and contained ~  107 exponentially growing tumor cells. 
Further evidence that  escaping P815  ceils were  resistant to the rejection response 
directed against P815  was obtained as follows. We found a  DBA/2  mouse that  had 
rejected Pl.aza  r to <100 cells, the detection threshold in our colony assay. This mouse 
was  then  injected  i.p.  with  control  Pl.aza  r  cells  obtained  from  the  ascites  of an 
irradiated animal together with Pl cells from an animal showing tumor escape. The 
results are shown  in  Fig.  3.  The  control cells were completely rejected whereas  the 
cells that  had escaped previously multiplied rapidly. 
Resistance of Escaping P815 Cells to an Anti-P815 CTL Clone.  We have described long- 
term syngeneic CTL clones that specifically lyse tumor  P815  (8). These CTL  clones 
could be derived from mice that had rejected P815 rum- variants, i.e., immunogenic 
variants obtained by mutagenesis that fail to form tumors in syngeneic mice. We used 
these clones to  determine whether  P815  antigens were  still present  on  the escaping 
tumor cells. 
Clone  CTL-P35:10  was  obtained  by  limiting dilution  stimulation  of spleen  cells 
that were primed and restimulated with rum- variant P35. This CTL clone lyses all 
P815-derived  cells and  is  inactive  on  syngeneic  tumor  L1210.  Three  independent 
escaping  tumor  cell  populations  were  tested  with  this  CTL  clone  (Fig.  4).  Their 
sensitivity was  considerably  lower  than  that  of control  ascitic cells obtained  from 
irradiated mice injected with P815.  The sensitivity of the three escaping populations 
to an anti-H-2  d CTL clone was very similar to that of the control population. Escaping 
population I, which showed  a  residual sensitivity to CTL-P35:10,  was subcloned on 
day 6  after its collection. All the clones were found  to be either completely resistant UYTTENHOVE,  MARYANSKI,  AND  BOON  1045 
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Fxc.  3.  A DBA/2 mouse was injected i.p. with 600 P1  cells (+).  On day 36, the same mouse 
was injected with a  mixture of 3 X  105 P1  cells collected from another DBA/2 mouse at the time of 
tumor escape (--O--)  and 3 X  10  ~ Pl.aza  r cells collected from the ascites on an irradiated animal 
(- -•-  -). The number of viable PI  and Pl.aza  r cells in the peritoneal cavity was estimated by 
plating samples in agar containing HAT or azaguanine, respectively. 
A  B 
~  10  m 
o  lo"1-  /  V";~  '.. 
' 
1  106~  ~#  /  D 
10  I"  N 
2( 
}  1°'i-.  ........  .......  1  ,,- 
o  1'o'  ~o'3'o'~'o  o.oal  o'.al  ;  I  a'c 
0.1  1  10 
DAYS  AFTER  INJECTION 
population ][ 
/Z 
0.1  1 
A  A  A 
o'.o31 o.~  I  ~ o1o31 c;.3 I 
0.1  1  0.1  1 
LYMPHOCYTE:TARGET RATIO 
Flo.  4.  Three DBA/2 mice were injected with 600 PI ceils. At various times thereafter, samples of 
the intraperitoneal fluid were collected and the number of living P1  cells was estimated in an agar 
colony test. Each curve in part A of the figure represents an individual mouse. At the times indicated 
by the arrows, the populations of P1  cells that escaped the immune rejection of these three mice 
were collected. The escaping P1 cells from mice I  (A), II (•), and III  (O)  were immediately mixed 
in vitro either with anti-P815 clone CTL-P35:10 (0) or with an anti-H-2  d CTL clone (O) at various 
effector-to-target  ratios.  After  a  3-h  incubation,  the  cells  were  plated  in  agar  and  the  colonies 
counted 4 d later (part B: I-III). The same test was performed on control P1 cells collected from an 
irradiated DBA/2 mice (part B: control). 
or completely sensitive  (Fig. 5 A-C and Table I). For population III, which appeared 
to be completely resistant,  no sensitive clone was found among the 24 tested. 
The clones appeared  to be stable in their resistance to CTL-P35:10. Four resistant 
clones from population  I  remained  completely resistant  when maintained  in culture 
for >1 mo, as shown for one clone in Fig. 5 D. In contrast, the sensitivity of uncioned 
escaping populations increased gradually with time. For instance, population I, which 1046  ESCAPE  OF  MOUSE  MASTOCYTOMA  P815 
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FIG.  5.  Sensitivity of individual  clones derived  from escaping population  I  (see  Fig.  4)  to anti- 
P815 clone CTL-P35:10  (0) and to an anti-H-2  d CTL clone (O) was measured in a 4-h 51Cr release 
assay. The targets in parts A,  B,  and C  were clones PI-20-1,  P1-20-4,  and  P1-20-13,  respectively. 
These clones were obtained by subcloning population I on day 6 after collection  and were tested 
within 14 d. The target in pane[ D was clone A that had been maintained in culture for 3 too. 
TABLE  I 
Proportion of Resistant or Sensitive  Clones in Escaping  PI Populations after  Various Times of Culture 
Escaping popula-  Day after removal  Number of clones  Number of sensi-  Number of resist- 
tions  analyzed  tive clones  ant clones 
I  6  26  6  2O 
17  27  14  13 
41  13  12  1 
II  0  24  8  16 
17  35  25  10 
III  0  24  0  24 
25  16  0  16 
Escaping P1  populations collected from mice I, II, and [II (see Fig. 4) were cultured in vitro and cloned at 
various times after their removal from the mice.  The sensitivity of each tumor clones obtained to the clone 
CTLoP35:10 was tested by the growth inhibition method (see Materials and Methods). 
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FIe.  6.  Escaping PI  cells  collected  from mouse I  (see Fig.  4)  were cultured  in  vitro.  At  various 
times after their removal from the mice, the sensitivity of these escaping P1  cells to the CTL clone 
anti-P815  P35:10  (0) and to an anti-H-2  d CTL clone (O) was measured by mixing the tumor cells 
with the CTL clones at various effector to target ratios. After an incubation of 3 h, the surviving P1 
cells were plated in agar and the colonies counted 4 d  thereafter. 
consisted predominantly  of resistant cells on the day of its collection, was found  to be 
completely  sensitive after 41  d  of culture  (Fig.  6).  Subcloning  experiments  indicated 
that  the sensitive clones overgrew  the  resistant  clones  (Table  I). We  verified  directly UYTTENHOVE, MARYANSKI, AND BOON  1047 
with  a  resistant  and a  sensitive clone of population  I  that  the former had a  slightly 
longer generation time. 
Presence of Multiple Antigenic Determinants on P815 and Related Antigen-loss Variants.  The 
emergence of P815 cells resistant to an anti-P815 CTL clone provided an explanation 
for the escape of tumor cells in animals  that  were clearly not in a  state of immuno- 
suppression.  However, it  remained  to be explained  how sensitive cells could still  be 
present  in  escaping  populations  at  a  time  when  newly  injected  P815  cells  were 
promptly  rejected.  One  possibility  was  that  these  sensitive  cells  would  have  lost 
another determinant  present  on P815 and thereby have a  much decreased sensitivity 
to the effector population present  in vivo. 
We  therefore  tested  other  CTL clones  specific  for P815  and  found  that  some of 
them  failed  to lyse escaping cell  clones  that  were still  sensitive  to CTL-P35:10.  For 
instance, clone CTL-PI:3, which was obtained after priming and restimulation  with 
irradiated  P815 cells, failed to lyse any clone obtained from populations I and III, not 
even those that were sensitive to CTL-P35:10.  Since the specificity defined by CTL- 
Pl:3  was  clearly  lost  more  readily,  it  was  labeled  P815A.  That  defined  by CTL- 
P35:10 was labeled P815B. Escaping tumor cell population ! consisted therefore of a 
mixture  of P815A-B + and  P815A-B- cells,  whereas  population  III consisted  exclu- 
sively of the latter type. 
To continue  the analysis of CTL-defined specificities  expressed  by P815 cells,  we 
isolated a  new CTL clone that recognized a  residual  specificity  (P815C)  on antigen- 
loss P815A-B- cells (Fig. 7). This anti-P815C clone (CTL-P89:15) was obtained from 
lymphocytes primed and restimulated  with turn- variant P89. Also presented in Fig. 
7 is the cytolytic activity of another CTL clone defining a  fourth specificity, P815D. 
To detect the P815D determinant,  we first isolated antigen-loss P815A-B-C- cells by 
subjecting  a  P815A-B-  clone  to  in  vitro  immunoselection  with  anti-P815C  clone 
P89:15.  The anti-P815D  clone  (CTL-P89:20)  was  then  obtained  by using resistant 
P815A-B-C-  cells  to  stimulate  spleen  cells  from  a  mouse  immunized  with  turn- 
variant  P89.  This  clone  lysed  antigen-loss  variants  PS15A-,  P815A-B-,  and 
P815A-B-C- as effectively as P1 targets. None of the four anti-P815 CTL clones lysed 
the syngeneic target  L1210. When tumor clones from escaping populations I and III 
were reanalyzed  using all  four anti-PSI5  CTL clones,  none was  found to have lost 
either the C  or D  determinant  (Table II). 
Additional antigen-loss variants were obtained by immunoselections with anti-PSI5 
CTL  clones  to  determine  which  of  the  P815  determinants  could  be  expressed 
independently.  Some  of these  variants  are  presented  in  Fig.  7,  where  antigen-loss 
consequent to tumor escape is indicated as ist and that resulting from in vitro selection 
as  isc.  The  existence  of P815  variants  of antigenic  types  A-B+C+D  +,  A-B-C+D  +, 
A+B+C-D+, and A+B+C+D  -  demonstrates  that, except for P815A and PSI5B, for all 
pairs of P815 determinants  the two members can be expressed  independently,  since 
either  one  can  be  lost  without  the  other.  Even  though  A-B  +  cells  were  found  in 
escaping populations, only A-B-C+D  + cells were obtained after in vitro selection with 
an anti-P815A CTL clone. No completely resistant variant was obtained after repeated 
selections with an anti-P815B CTL clone. 
Tumorigenicity of P815 Antigen-loss  Variants.  Cells  (600)  from  P815A-B+C+D  +  or 
P815A-B-C+D  +  clones  isolated  from  escaping  population  I  were  injected  i.p.  into 
normal  DBA/2  mice.  In all  mice  the cells  grew  progressively without  a  detectable 1048 
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Fro.  7.  The cytolytic activity of anti-P815A  (CTL-PI:3), anti-P815B  (CTL-P35:10),  anti-P815C 
(CTL-P89:15), and anti-P815D (CTL-P89:20) CTL clones was measured in a 4-h 51Cr release  assay. 
The target  cells  were derived  from the  P1  clone of P815  after escape in  vivo  (ist),  after  in  vitro 
selection with CTL clones (isc), or by a combination of both. All the cells used as targets were clones 
obtained  from  populations that  were  selected  as  follows:  Pl:  original  tumorigenic  P815  clone; 
Pl.istA  :  clone  P1-20-13  from  escaping  population  I  (Fig.  4);  Pl.istA-B-:  clone  PI-2&4  from 
escaping population I;  Pl.istA-B-iscC-:  previous clone selected  twice with anti-P8[5C CTL clone 
P89:15;  Pl.istA-B  iscC  iscD  :  previous clone  selected  three  times with  anti-P815D  CTL  clone 
P89:20;  Pl.iscC-:  PI  selected  twice with anti-P815C  CTL clone P89:15;  Pl.istA-iscC-:  clone Pl- 
20-13  selected  twice with anti-P815C  CTL  clone  P89:15;  Pl.iscD  :  P1  selected  twice with anti- 
P815D CTL clone P89:10;  Pl.iscA-B  : P1  selected  once with anti-P815A CTL clone PI:3. 
"FABLE II 
P815-specij'ic  Determinants on Escaping  Cells 
Escaping popula-  Number of clones  Antigenic types 
tions  analyzed  ~  " 
I  16  10:  A-B+C+D  ÷ 
6: A-B  C+D  + 
III  16  16:  A-B  C+D  + 
Escaping  P1  populations  collected  &ore  mice  I  and  III  (see  Fig.  4)  were 
cultured in vitro and cloned.  The sensitivity of each clone obtained to clone 
CTL-PI:3  (anti-P815A), clone CTL-P35:10  (anti-P815B),  clone CTL-P89:15 
clone  (anti-P815C)  and  clone  CTL-P89:20  (anti-P815D)  was  tested  by  the 
growth inhibition method (see Materials and Methods). 
rejection  phase,  confirming  the  importance  of antigen  P815A  in  the  rejection  of the 
tumor.  Representative  data  obtained  with  escaping  populations  or with  antigen-loss 
variants  is shown  in  Fig.  8. 10 9 
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FIG.  8.  DBA/2 mice were injected intraperitoneally with 600 cells obtained from escaping popu- 
lation I  (see  Fig. 4)  after 6  d  of culture or with 600 cells of P815A-B+C÷D  + or  P815A-B-C+D  + 
isolated from  population I.  At  various times thereafter, samples of the intraperitoneal fluid were 
collected and  the number of living P815 cells was estimated in  an  agar colony test.  Each curve 
represents an individual mouse and ends on the last sampling before the death of the animal. 
Discussion 
Our results indicate that, when mastocytoma P815-X2 escapes from quasi-complete 
elimination due to syngeneic immune rejection, the tumor cells resume their expansion 
while  the  host  is  not  in  an  immunosuppressed  state,  as  shown  by  the  rejection  of 
newly injected P815 cells. We also find that the emergent tumor cells are less sensitive 
than the original cells to CTL directed against  P815. A similar observation was made 
by Biddison and Palmer (5) with the P815-Y tumor subline. Our results indicate that 
the  resistance  is  not  due  to  modulation  but  to  the  presence  of stable  variants  that 
have lost  some of the  tumor-associated  antigenic  specificities  present  on  P815.  The 
progressive reversal toward sensitivity to some anti-P815 CTL clones that is observed 
with  escaping tumor cell  populations  maintained  in culture  appears  to be due  to a 
slight growth advantage of the clones that have retained the corresponding antigenic 
specificity. 
Our findings are consistent with other reports indicating that for malignant cells of 
high  immunogenicity,  the  cells  found in  progressive tumors or metastases  are often 
largely resistant  to CTL directed  against  the  initial  population  (12-15).  Our use of 
CTL  clones  and  of both  in  vivo  and  in  vitro  selection  procedures  allowed  us  to 
distinguish  on  P815  at  least  four antigenic  specificities  capable of eliciting  a  T  cell 
cytolytic response in the syngeneic host.  From these,  only two appear to be selected 
against  in the course of the escape of the tumor cells, suggesting that  P815 does not 
elicit an efficient response against  the two other specificities. 
Whereas our results exclude that suppressor T  cells provide a sufficient explanation 
for the escape of P815, we do not think that they are incompatible with the existence 
of suppressor T  cells affecting specifically the response against  P815.  Dye and North 
(16)  conclusively demonstrated  that  specific suppressor  T  lymphocytes constitute  a 1050  ESCAPE OF MOUSE MASTOCYTOMA P815 
major obstacle  to  adoptive  immunotherapy directed  against  P815  present  in  mice 
bearing P815 tumors. Also, P815 tumor cells  injected subcutaneously were observed 
to form tumors less rapidly in mice that had received an irradiation dosage reported 
to  affect  preferentially  T  suppressor  cells  (17).  Finally,  specific  suppressor  cells 
inhibiting the maturation of anti-P815 CTL have been reported to be present in the 
spleen of mice carrying advanced tumors (4, 7). However, we found that spleen cells 
of mice carrying advanced tumors were still  capable of being stimulated  in  vitro to 
form active CTL populations, provided metastatic tumor cells were eliminated  from 
the splenic population. This could be achieved by injecting mice with an azaguanine- 
resistant  P815 variant and by treating the spleen cells with HAT (18). 
In the assessment of the relative role of antigen-loss variants and suppressor T  cells 
in  the  escape  of P815,  it  may  be  useful  to  distinguish  three  types  of situations 
encountered  in  the  rejection  of this  tumor.  In  a  first,  the  tumor  cells  multiply 
exponentially  for  ~10  d,  the  number  of tumor  cells  then  remains  approximately 
stationary for a  few days, and finally the tumor resumes its progressive growth. The 
stationary phase probably results from an equilibrium between the multiplication of 
the tumor cells and their destruction by the immune defenses.  It is therefore plausible 
that suppressor T  cells  play a major role in resolving this equilibrium in favor of the 
tumor cells.  In a  second situation, the period of exponential growth is followed by a 
nearly complete elimination of the tumor cells  followed in turn by a  rapid multipli- 
cation of a surviving fraction of the tumor cells.  On the basis of our results, we think 
that the emergence of these tumor cells  can be explained entirely by the selection of 
antigen-loss variants.  A  third  situation  is sometimes observed where,  after a  nearly 
complete elimination  of P815,  a  very low and  stationary number of tumor cells  is 
found in the peritoneal cavity for a  period varying from a  few days to a  few weeks. 
Eventually the tumor cells resume their progressive growth. This situation corresponds 
to that referred by Weinhold  (19) as the tumor dormant state.  Our results  indicate 
that during the dormant period and the secondary emergence of the tumor the mice 
are not in a  imnmnosuppressed state and that the emergent tumor cells  are antigen- 
loss variants.  However, we have no explanation for the mechanism whereby residual 
tumor cells  remain  present  in  low numbers  for weeks.  It will  be of great  interest  to 
examine the antigenic determinants present on these dormant cells. 
Our analysis demonstrates that P815-X2 carries at least four antigenic determinants 
recognized by different  CTL clones. Considering that  P815 is used by a  number of 
groups to study tumor rejection, it would be useful to type for the expression of these 
antigens  P815  cells  from  different  laboratories  in  order  to  facilitate  comparison of 
results.  Our  antigen-loss  variants  may also  become useful  in  determining  whether 
tumor-associated specificities defined by antibodies coincide with specificities defined 
by CTL clones. 
The recognition that  tumor cells  may carry multiple  tumor-associated transplan- 
tation antigens and that they may escape the host defenses by the loss of only some of 
these antigens may be of significance for immunotherapy. It suggests that, as in some 
situations encountered in chemotherapy, it may be important to secure a simultaneous 
response against multiple targets, so as to minimize the emergence of resistant variants. 
Summary 
Even  though  mastocytoma P815  often  undergoes  a  nearly complete rejection  in 
syngeneic mice, the tumor cells almost always escape to form progressive tumors. We UYTI'ENHOVE,  MARYANSKI, AND BOON  1051 
found  that  this  was  not  due  to  the  establishment  of an  immunosuppressed  state 
because genetically marked P815 cells, that were injected in mice where tumor escape 
was occurring, were readily rejected. 
An analysis of escaping tumor cell populations with anti-P815 cytolytic T  lympho- 
cyte (CTL) clones showed the presence of stable resistant variants. Using antigen-loss 
variants found in escaping populations or selected in vitro with CTL clones, we were 
able to define four different tumor-associated antigenic specificities, each recognized 
by a specific CTL clone. One of these specificities was absent from all escaping tumor 
cells and another had been lost by some of them. 
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